SCHEMBL316976

SCHEMBL316976

COc1ccc2c(c1)CCC=C2C

nearest known ligand 0.66

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MPO P05164 1/20 0.66
CYP1A2 P05177 1/20 0.45
CYP2D6 P10635 1/20 0.45
ELANE P08246 1/20 0.44
ABCB1 P08183 1/20 0.44
METAP1 P53582 1/20 0.44
CYP19A1 P11511 2/20 0.43
CYP11B2 P19099 2/20 0.43
KDM4E B2RXH2 2/20 0.43
BCL2 P10415 1/20 0.43
ALDH1A1 P00352 1/20 0.43
MAPT P10636 1/20 0.43
HTT P42858 1/20 0.43
CYP26A1 O43174 1/20 0.43
GLA P06280 1/20 0.42
MIF P14174 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12119770 1.00 MPO (0.66) MPOCYP1A2CYP2D6ELANEABCB1
SCHEMBL11094766 0.86 MPO (0.53) MPOABCB1METAP1CYP19A1CYP11B2
SCHEMBL31285043 0.82 MPO (0.66) MPOCYP1A2CYP2D6ELANEABCB1
SCHEMBL29248715 0.81 MPO (0.47) MPOCYP1A2CYP2D6METAP1CYP19A1
SCHEMBL3277069 0.81 MPO (0.45) MPOKDM4EALDH1A1
SCHEMBL27001686 0.81 MPO (0.64) MPOCYP1A2CYP2D6ELANEABCB1
SCHEMBL6552114 0.81 MPO (0.64) MPOCYP1A2CYP2D6ELANEABCB1
SCHEMBL30640469 0.81 MPO (0.64) MPOCYP1A2CYP2D6ELANEABCB1
SCHEMBL17108416 0.78 MPO (0.59) MPOCYP1A2CYP2D6METAP1CYP19A1
SCHEMBL15818200 0.78 MPO (0.74) MPOCYP1A2CYP2D6ELANEABCB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3782977-A1 CYCLOPROPANATION METHOD AND REAGENT Fundació Privada Institut Català d'Investigació Química (ICIQ) (ES) 2021-02-24 EP disclosed
US-10774060-B2 Oxone-aceton mediated metal free preparation of syn-diols COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2020-09-15 US disclosed
US-10774060-B2 Oxone-aceton mediated metal free preparation of syn-diols COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2020-09-15 US disclosed
US-20160168114-A1 Oxone-Aceton Mediated Metal Free Preparation of Syn-Diols COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2016-06-16 US disclosed
US-20160168114-A1 Oxone-Aceton Mediated Metal Free Preparation of Syn-Diols COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2016-06-16 US disclosed
US-20160168114-A1 Oxone-Aceton Mediated Metal Free Preparation of Syn-Diols COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2016-06-16 US disclosed
WO-2014207766-A1 OXONE-ACETONE MEDIATED METAL FREE PREPARATION OF SYN-DIOLS COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2014-12-31 WO disclosed
WO-2014207766-A1 OXONE-ACETONE MEDIATED METAL FREE PREPARATION OF SYN-DIOLS COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2014-12-31 WO disclosed
US-8592458-B2 Alpha7 nicotinic receptor selective ligands UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2013-11-26 US disclosed
US-20120094943-A1 ALPHA 7 NICOTINIC RECEPTOR SELECTIVE LIGANDS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2012-04-19 US disclosed
EP-1073640-A1 NAPHTHALENE DERIVATIVES, THEIR PRODUCTION AND USE Takeda Chemical Industries, Ltd. (JP) 2001-02-07 EP disclosed
US-6054474-A Heterocyclic compounds for the treatment of pain and use thereof BIOCHEM PHARMA, INC. (CA) 2000-04-25 US disclosed
US-5990104-A INHIBITING NMDA RECEPTOR ACTIVATION BY ADMINISTERING DERIVATIVES OF GIVEN FORMULA, SUCH AS 5,6,7,8,9,11,12-HEPTAHYDRO-3-HYDROXY-5-METHYL-10-THIA-5,11 -METHANOBENZOCYCLODECEN-13-AMINE (SULPHAZOCINE) BIOCHEM PHARMA, INC. (CA) 1999-11-23 US disclosed
WO-1999054309-A1 NAPHTHALENE DERIVATIVES, THEIR PRODUCTION AND USE TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1999-10-28 WO disclosed
EP-0850234-A1 NOVEL HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF PAIN AND USE THEREOF BIOCHEM PHARMA INC (CA) 1998-07-01 EP disclosed
EP-0840731-A1 POLYCYCLIC ALCALOID-DERIVATIVES AS NMDA-RECEPTOR ANTAGONISTS BIOCHEM PHARMA INC (CA) 1998-05-13 EP disclosed
WO-1997003979-A1 POLYCYCLIC ALCALOID-DERIVATIVES AS NMDA-RECEPTOR ANTAGONISTS BIOCHEM PHARMA INC. (CA) 1997-02-06 WO disclosed
WO-1997003978-A1 NOVEL HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF PAIN AND USE THEREOF BIOCHEM PHARMA INC. (CA) 1997-02-06 WO disclosed
US-5491233-A Catalytic asymmetric reduction of trisubstituted olefins MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 1996-02-13 US disclosed
US-5442119-A Catalytic asymmetric reduction of trisubstituted olefins MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 1995-08-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120094943-A1 ALPHA 7 NICOTINIC RECEPTOR SELECTIVE LIGANDS CHRNA7, CHRNA10, CHRNA5 MPO 2427/4885CYP1A2 1218/4885CYP2D6 2319/4885
US-20160168114-A1 Oxone-Aceton Mediated Metal Free Preparation of Syn-Diols SQLE, OXER1, OXA1L MPO 1767/4885CYP1A2 147/4885CYP2D6 102/4885
US-10774060-B2 Oxone-aceton mediated metal free preparation of syn-diols SQLE, OXER1, OXA1L MPO 1767/4885CYP1A2 147/4885CYP2D6 102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.